SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Jingyin Dong, Jianyang Wei, Limei Zhong, Qiong Yang, Jiuling Tuo, Pan Zhou, Jie Fang, Weiping Cai, Xiaoyi Sun, Jie Zhou, Ribavirin enhances myeloid-derived suppressor cell differentiation through CXCL9/10 downregulation, Immunopharmacology and Immunotoxicology, 2014, 36, 6, 412

    CrossRef

  2. 2
    Mario U. Mondelli, The multifaceted functions of ribavirin: Antiviral, immunomodulator, or both?, Hepatology, 2014, 60, 4
  3. 3
    Jamal Sarvari, Hossin Norozian, Mohamad Reza Fattahi, Neda Pirbonyeh, Afagh Moattari, The Role of Interferon Gamma Gene Polymorphism (+874A/T, +2109A/G, and -183G/T) in Response to Treatment Among Hepatitis C Infected Patients in Fars Province, Southern Iran, Hepatitis Monthly, 2014, 14, 1

    CrossRef

  4. 4
    Henry Ogbomo, Martin Michaelis, Behric Altenbrandt, Hans Wilhelm Doerr, Jindrich Cinatl, A novel immunomodulatory mechanism of ribavirin in suppressing natural killer cell function, Biochemical Pharmacology, 2010, 79, 2, 188

    CrossRef

  5. 5
    Marco Derudas, Andrea Brancale, Lieve Naesens, Johan Neyts, Jan Balzarini, Christopher McGuigan, Application of the phosphoramidate ProTide approach to the antiviral drug ribavirin, Bioorganic & Medicinal Chemistry, 2010, 18, 7, 2748

    CrossRef

  6. 6
    Chun-Hao Chen, Ming-Lung Yu, Evolution of Interferon-Based Therapy for Chronic Hepatitis C, Hepatitis Research and Treatment, 2010, 2010, 1

    CrossRef

  7. 7
    David E. Kaplan, Fusao Ikeda, Yun Li, Nobuhiro Nakamoto, Sutharsan Ganesan, Mary E. Valiga, Frederick A. Nunes, K. Rajender Reddy, Kyong-Mi Chang, Peripheral virus-specific T-cell interleukin-10 responses develop early in acute hepatitis C infection and become dominant in chronic hepatitis, Journal of Hepatology, 2008, 48, 6, 903

    CrossRef

  8. 8
    Paul Martin, Donald M Jensen, Ribavirin in the treatment of chronic hepatitis C, Journal of Gastroenterology and Hepatology, 2008, 23, 6
  9. 9
    Heinz Zoller, Wolfgang Vogel, Nanomedicines in the treatment of patients with hepatitis C co-infected with HIV ? focus on pegylated interferon-alpha, International Journal of Nanomedicine, 2006, 1, 4, 399

    CrossRef

  10. 10
    Bin Gao, Feng Hong, Svetlana Radaeva, Host factors and failure of interferon-α treatment in hepatitis C virus, Hepatology, 2004, 39, 4
  11. 11
    MASAAKI SHIINA, KOJU KOBAYASHI, HIROKO SATOH, HIROFUMI NIITSUMA, YOSHIYUKI UENO, TOORU SHIMOSEGAWA, Ribavirin upregulates interleukin-12 receptor and induces T cell differentiation towards type 1 in chronic hepatitis C, Journal of Gastroenterology and Hepatology, 2004, 19, 5
  12. 12
    Uichiro Fuchizaki, Shuichi Kaneko, Yasunari Nakamoto, Yoshihiro Sugiyama, Kenichi Imagawa, Mikio Kikuchi, Kenichi Kobayashi, Synergistic antiviral effect of a combination of mouse interferon-α and interferon-γ on mouse hepatitis virus, Journal of Medical Virology, 2003, 69, 2
  13. 13
    Silvia Lee, Gerry C Macquillan, Niamh M Keane, James Flexman, Gary P Jeffrey, Martyn Ah French, Jean Brochier, Patricia Price, Immunological markers predicting outcome in patients with hepatitis C treated with interferon-alpha and ribavirin, Immunology and Cell Biology, 2002, 80, 4, 391

    CrossRef

  14. 14
    A. KASER, D. NOVICK, M. RUBINSTEIN, B. SIEGMUND, B. ENRICH, R. O. KOCH, W. VOGEL, S. H. KIM, C. A. DINARELLO, H. TILG, Interferon-α induces interleukin-18 binding protein in chronic hepatitis C patients, Clinical & Experimental Immunology, 2002, 129, 2
  15. 15
    A. BERGAMINI, M. CEPPARULO, F. BOLACCHI, A. ARACO, G. TISONE, D. OMBRES, G. ROCCHI, M. ANGELICO, Ribavirin increases mitogen- and antigen-induced expression of CD40L on CD4+ T cells in vivo, Clinical & Experimental Immunology, 2002, 130, 2
  16. 16
    Noel J C Snell, Ribavirin - current status of a broad spectrum antiviral agent, Expert Opinion on Pharmacotherapy, 2001, 2, 8, 1317

    CrossRef